XOMA Royalty (XOMA) Change in Receivables (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Change in Receivables came in at -$325000.0 in Q1 2026, down 108.77% year-on-year from $3.7 million in Q1 2025, and down 126.23% quarter-over-quarter from $1.2 million in Q4 2025.
XOMA Royalty (XOMA) Change in Receivables (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Change in Receivables across 17 years of filings, most recently posting -$325000.0 for Q1 2026.
- Change in Receivables for Q1 2026 came in at -$325000.0, down 108.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.6 million (down 128.95% YoY), and the FY2025 annual result was $2.4 million, up 190.54% from the prior year.
- Change in Receivables came in at -$325000.0 for Q1 2026 at XOMA Royalty, down from $1.2 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $3.7 million in Q1 2025 to a low of -$3.7 million in Q2 2025.
- The 5-year median for Change in Receivables is $11000.0 (2022), against an average of $219470.6.
- Across the five-year window, Change in Receivables soared 6506.67% in 2023 and plunged 20120.0% in 2024, its largest moves.
- XOMA Royalty's Change in Receivables stood at -$15000.0 in 2022, then jumped by 6506.67% to $961000.0 in 2023, then fell by 17.38% to $794000.0 in 2024, then surged by 56.05% to $1.2 million in 2025, then tumbled by 126.23% to -$325000.0 in 2026.
- The last three Change in Receivables figures came in at -$325000.0 (Q1 2026), $1.2 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -4.08 Mn |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | -325,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -325,000.00 |
| Mar 31, 2026 | -325,000.00 |
| Dec 31, 2025 | 1.24 Mn |
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Sep 30, 2025 | 1.21 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Jun 30, 2025 | -3.73 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Mar 31, 2025 | 3.71 Mn |
| Dec 31, 2024 | 794,000.00 |
| Dec 31, 2024 | 794,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Sep 30, 2024 | 519,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Mar 31, 2024 | -1.00 Mn |
| Mar 31, 2024 | -1.00 Mn |
| Dec 31, 2023 | 961,000.00 |
| Dec 31, 2023 | 961,000.00 |